DeESCALaTE Collect
De-ESCALaTE Collect
Determination of epidermal growth factor receptor-inhibitor (cetuximab) versus standard chemotherapy (cisplatin) early and late toxicity events in human papillomavirus-positive oropharyngeal squamous cell carcinoma
Summary:
Oropharyngeal squamous cell carcinoma (OPSCC) incidence is increasing rapidly in the developed world. This has been attributed to a rise in Human Papillomavirus (HPV) infection. HPV+OPSCC is considered a distinct disease entity, affecting younger patients and has a good prognosis following treatment. Subsequently, patients can live with the considerable side effects for several decades.
Radiotherapy and cetuximab (Epidermal Growth Factor Receptor-inhibitor) have demonstrated similar efficacy to ‘platin’ c
De-ESCALaTE Collect
Blood, Oral Fluid and Tissue Sample Collection & Storage.
40mls blood at baseline, 3 months & 12 months post treatment end, also at recurrence or progression for relevant patients.
Oral fluid at baseline, 3 months & 12 months post treatment end, also, at
recurrence or progression for relevant patients. Blood and oral rinse samples are processed and stored at In Hanse.
Formalin-fixed paraffin-embedded (FFPE) tissue blocks of diagnostic biopsy specimens and, if applicable, post treatment biopsies and when neck dissection has been performed and biopsies at recurrence or progression.
Collected and stored at InHANSE.
Contact Details
InHANSE
2nd Floor Robert Aitken Building
School of Cancer Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
Tel: +44 (0) 121 414 6547
Fax: +44 (0) 121 414 8046
Email: enquiries@inhanse.org
